Collectively, current evidence from RCT subgroups, observational studies, and mechanistic data supports the biological plausibility and clinical relevance of complementary cardiovascular and kidney benefits with combined SGLT2i and GLP-1RA therapy (Table 2)
The most common adverse events were dose-related gastrointestinal symptoms, primarily nausea, which were previously seen with GLP-1 receptor agonists
It is foreseeable that GLP-1 weight loss drugs with superior effects and safety will become the next blockbuster
A novel oral carnitine challenge test (OCCT) was recently developed, in which the detection of Ihubacter massiliensis and/or Emergencia timonensis in the human gut can synergistically contribute to diagnosing high-TMAO producers, with 43% sensitivity and 97% specificity (95)
Game changer
And a booster taken alongside a prescription GLP-1 is redundant spending, not a risk